Indian equity benchmark indices opened lower on Friday, with profit-taking across sectors outweighing positive news from corporate earnings and anticipated progress in India–US trade discussions. By 9:22 a.m. IST, the Nifty 50 dropped 0.64% to 25,346.9, while the BSE Sensex slipped 0.67% to 82,740.13.
Sampre Nutritions Limited, a confectionery and nutraceutical manufacturer, announced its financial performance for the quarter and half year ended September 30, 2025.
Sampre Nutritions Limited reported its financial performance for Q2FY26, with revenue from operations rising 37.5% year-on-year to ₹9.99 crore, compared to ₹7.27 crore in Q2FY25. Net profit surged over six-fold to ₹89.55 lakh from ₹12.45 lakh last year, reflecting a year-on-year growth of 620%. For H1FY26, revenue increased 77% to ₹20.86 crore from ₹11.78 crore, while net profit rose over six times to ₹160.41 lakh compared to ₹22.34 lakh in the same period last year.
On November 5, 2025, the Board of Directors approved the issuance of 17.70 lakh equity shares of ₹5 face value each at ₹42 per share to promoters Mr. Brahma Gurbani and Ms. Meera Gurbani. The shares will be allotted through conversion of unsecured loans worth ₹7.43 crore on a preferential basis. The issue price of ₹42 per share, after adjusting for stock split and bonus, is higher than the current adjusted market price of ₹35.35 per share.
The company entered into a manufacturing agreement with Reliance Consumer Products Ltd. (RCPL) for the manufacture and supply of nutraceutical and food products. The agreement is expected to generate business worth ₹12–15 crore annually over three years. Sampre will produce and supply confectionery items such as hard-boiled candies, lollipops, and toffees under RCPL’s quality standards and specifications.
Sampre Nutritions approved the issuance of Foreign Currency Convertible Bonds (FCCBs) aggregating to USD 4 crore (₹355.06 crore) through 400 FCCBs of USD 1 lakh each. The proceeds will be utilized to expand the company’s presence in emerging markets such as Egypt and Liberia. Aries Capital Limited has been appointed as the Lead Arranger for the listing and underwriting process. The FCCBs were made available on the AFRINEX Exchange, Mauritius, between October 10 and October 15, 2025.
In August 2025, Sampre Nutritions entered into a manufacturing agreement with Tolaram Wellness Ltd., Nigeria, to produce nutraceutical and food products. This contract is expected to generate ₹10 crore in annual business, amounting to ₹30 crore over three years. The company also signed a three-year manufacturing agreement with Rama Exports on August 19, 2025, projected to bring in ₹15 crore in business, further strengthening its nutraceutical operations and export partnerships.
Sampre Nutritions Limited was awarded the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact, highlighting its growing reputation in the confectionery and nutraceutical sectors.
On Friday, Sampre Nutrition share price locked in the 2% lower circuit at ₹138.60 per share. Earlier, the stock price had maintained a streak of 90 upper circuits, logging returns of over 550%.
For android only